Particle.news
Download on the App Store
11 ARTICLES
·
last mo.

Sun Pharma Shares Drop 5% Following Mixed Q4 FY25 Results

The pharmaceutical giant reported an 8% revenue increase but a 19% profit decline, with softer FY26 growth guidance and plans for $100 million in specialty investments.

Sun Pharma secures licensing agreement with Aclaris Therapeutics for innovative drug development | Image: Sun Pharma
Image
Image
Sun Pharma shares fall 5% amid mixed Q4FY25 earnings

Overview

  • Sun Pharma's Q4 FY25 net profit fell 19% year-on-year to Rs 2,153.9 crore, missing analyst expectations.
  • Revenue for the quarter rose 8% to Rs 12,958.8 crore, while EBITDA grew 22.4% to Rs 3,715.9 crore, reflecting operational efficiency.
  • The company announced a final dividend of Rs 5.50 per share, with July 7, 2025 set as the record date pending shareholder approval.
  • Shares fell nearly 5% following the results, as investors reacted to the profit decline and conservative FY26 revenue guidance of mid- to high-single-digit growth.
  • Management plans $100 million in FY26 investments for the US launches of Leqselvi and Unloxcyt, aimed at expanding its specialty portfolio despite near-term margin pressures.